-
1 Comment
Microbot Medical Inc is currently in a long term downtrend where the price is trading 3.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Microbot Medical Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.0% to $-9 since the same quarter in the previous year.
Finally, its free cash flow grew by 357.1% to $5M since the same quarter in the previous year.
Based on the above factors, Microbot Medical Inc gets an overall score of 3/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US59503A2042 |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
PE Ratio | None |
---|---|
Target Price | 9 |
Beta | 1.4 |
Market Cap | 87M |
Dividend Yield | None |
Microbot Medical Inc., a clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MBOT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025